Inflammation turns mutation deadly
A simple viral infection in the lungs of rats can become a lethal form of pulmonary hypertension if a common mutation is present, new Stanford research shows.
Success in rheumatoid arthritis trial
In a large trial led by a Stanford investigator, an experimental drug produced clinically meaningful improvements for rheumatoid arthritis patients unresponsive to existing treatments.
Possible drug target for cardiomyopathy
Stanford researchers have uncovered how a genetic mutation contributes to a heart disease known as familial dilated cardiomyopathy. Existing drugs correct the defect in heart cells grown in a petri dish, suggesting a new therapeutic target.
Chronic fatigue syndrome biomarker found
Stanford scientists devised a blood-based test that accurately identified people with chronic fatigue syndrome, a new study reports.
Drug reduces kidney failure in diabetics
Canagliflozin, a drug approved to lower glucose levels in diabetic patients, can slow the progression of kidney disease, according to a study co-authored by a Stanford Medicine researcher.
Possible ‘bubble boy’ disease therapy
In preclinical trials, Stanford scientists and their collaborators harnessed the gene-editing system CRISPR-Cas9 to replace the mutated gene underpinning the devastating immune disease.
Possible zinc strategy for diabetes
To treat diabetes directly, rather than manage its symptoms, doctors need a way to get drugs to cells that produce insulin. The key, Stanford researchers report, may be those cells’ affinity for zinc.
Glucose spikes seen in healthy people
A study out of Stanford in which blood sugar levels were continuously monitored reveals that even people who think they’re “healthy” should pay attention to what they eat.
Peering into kids’ bones
Mary Leonard, chair of the Department of Pediatrics at Stanford, works to understand exactly how chronic diseases hurt children’s bone health.
Diabetes center gets $7.7 million
With the grant, Stanford joins 16 other federal research centers across the country dedicated to the prevention and treatment of diabetes.
Psoriatic arthritis drug shows promise
In a randomized clinical trial conducted by researchers at Stanford and more than 100 other medical centers, psoriatic arthritis patients given an injectable biologic drug for 24 weeks showed substantial improvement compared with patients who received placebo injections.
- Big Data
- Cardiovascular Health
- Chemical Biology
- Chronic Disease
- Developmental Biology
- Global Health
- Health Policy
- Infectious Disease
- Mental Health
- Patient Care
- Precision Health
- Preventive Medicine
- Stem Cells
- Women's Health